Noushin Brealey

2.1k total citations · 1 hit paper
32 papers, 1.4k citations indexed

About

Noushin Brealey is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Pharmacology. According to data from OpenAlex, Noushin Brealey has authored 32 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pulmonary and Respiratory Medicine, 22 papers in Physiology and 3 papers in Pharmacology. Recurrent topics in Noushin Brealey's work include Asthma and respiratory diseases (22 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (21 papers) and Inhalation and Respiratory Drug Delivery (17 papers). Noushin Brealey is often cited by papers focused on Asthma and respiratory diseases (22 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (21 papers) and Inhalation and Respiratory Drug Delivery (17 papers). Noushin Brealey collaborates with scholars based in United Kingdom, United States and India. Noushin Brealey's co-authors include David A. Lipson, Maggie Tabberer, Steven Pascoe, David A. Lomas, Mark T. Dransfield, Dave Singh, Gerard J. Criner, David Halpin, Frank Barnhart and Robert A. Wise and has published in prestigious journals such as New England Journal of Medicine, American Journal of Respiratory and Critical Care Medicine and European Respiratory Journal.

In The Last Decade

Noushin Brealey

31 papers receiving 1.3k citations

Hit Papers

Once-Daily Single-Inhaler Triple versus Dual Therapy in P... 2018 2026 2020 2023 2018 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD
    2018 758 citations David A. Lipson, Frank Barnhart et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Noushin Brealey United Kingdom 13 1.3k 964 62 44 38 32 1.4k
Jean Brooks United States 11 1.2k 1.0× 936 1.0× 55 0.9× 43 1.0× 36 0.9× 22 1.3k
Sally Kilbride United States 14 1.6k 1.3× 1.2k 1.3× 67 1.1× 58 1.3× 35 0.9× 36 1.7k
Frank Barnhart United States 7 1.2k 1.0× 900 0.9× 66 1.1× 56 1.3× 31 0.8× 15 1.3k
Lucy Frith United Kingdom 10 711 0.6× 570 0.6× 38 0.6× 19 0.4× 17 0.4× 18 815
Marcia L. Erbland United States 10 668 0.5× 375 0.4× 61 1.0× 85 1.9× 34 0.9× 15 877
Earl St. Rose United States 14 754 0.6× 526 0.5× 22 0.4× 55 1.3× 11 0.3× 47 894
Pilar Román Sánchez Spain 7 478 0.4× 227 0.2× 32 0.5× 56 1.3× 35 0.9× 9 526
A. Dixmier France 7 452 0.4× 121 0.1× 23 0.4× 75 1.7× 20 0.5× 23 549
Nassrin Payvandi United Kingdom 4 389 0.3× 183 0.2× 21 0.3× 74 1.7× 22 0.6× 8 472
Shireen Mirza United States 6 311 0.2× 118 0.1× 28 0.5× 84 1.9× 6 0.2× 11 469

Countries citing papers authored by Noushin Brealey

Since Specialization
Citations

This map shows the geographic impact of Noushin Brealey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Noushin Brealey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Noushin Brealey more than expected).

Fields of papers citing papers by Noushin Brealey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Noushin Brealey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Noushin Brealey. The network helps show where Noushin Brealey may publish in the future.

Co-authorship network of co-authors of Noushin Brealey

This figure shows the co-authorship network connecting the top 25 collaborators of Noushin Brealey. A scholar is included among the top collaborators of Noushin Brealey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Noushin Brealey. Noushin Brealey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Brealey, Noushin, et al.. (2018). Hair analysis to monitor adherence to prescribed chronic inhaler drug therapy in patients with asthma or COPD. Pulmonary Pharmacology & Therapeutics. 51. 59–64. 22 indexed citations
3.
4.
Halpin, David, Ruby Birk, Noushin Brealey, et al.. (2018). Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses. ERJ Open Research. 4(2). 119–2017. 13 indexed citations
5.
Naya, Ian, Chris Compton, Afisi Ismaila, et al.. (2018). Preventing clinically important deterioration with single-inhaler triple therapy in COPD. ERJ Open Research. 4(4). 47–2018. 18 indexed citations
6.
Lipson, David A., Frank Barnhart, Noushin Brealey, et al.. (2018). Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. New England Journal of Medicine. 378(18). 1671–1680. 758 indexed citations breakdown →
7.
Tabberer, Maggie, David A. Lomas, Ruby Birk, et al.. (2018). Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life. Advances in Therapy. 35(1). 56–71. 21 indexed citations
8.
Mehta, Rashmi, Misba Beerahee, Noushin Brealey, et al.. (2018). Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD. The Journal of Clinical Pharmacology. 58(11). 1461–1467. 3 indexed citations
9.
Lipson, David A., Helen Barnacle, Ruby Birk, et al.. (2017). FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 196(4). 438–446. 226 indexed citations
10.
Ismaila, Afisi, Ruby Birk, Dhvani Shah, et al.. (2017). Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial. Advances in Therapy. 34(9). 2163–2172. 13 indexed citations
11.
12.
Mehta, Rashmi, et al.. (2016). Systemic Exposures of Fluticasone Propionate and Salmeterol Following Inhalation via Metered Dose Inhaler with the Mini Spacer Compared with the Aerochamber Plus Spacer. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 29(4). 386–392. 2 indexed citations
13.
Pascoe, Steven, David A. Lipson, Nicholas Locantore, et al.. (2016). A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. European Respiratory Journal. 48(2). 320–330. 60 indexed citations
14.
Prime, David, Wilfried De Backer, Melanie Hamilton, et al.. (2015). Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA ® Dry Powder Inhaler. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 28(6). 486–497. 49 indexed citations
15.
Brealey, Noushin, et al.. (2015). Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics. 53(9). 753–764. 17 indexed citations
16.
Kelleher, Dennis, Lee Tombs, Andrew Preece, Noushin Brealey, & Rashmi Mehta. (2014). A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects. Pulmonary Pharmacology & Therapeutics. 29(1). 49–57. 17 indexed citations
17.
18.
Mehta, Rashmi, Kelly Hardes, Noushin Brealey, et al.. (2014). Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study. International Journal of COPD. 10. 15–15. 10 indexed citations
19.
Mehta, Rashmi, Kelly Hardes, Dennis Kelleher, et al.. (2013). Effect of moderate hepatic impairment (MHI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK). 42. 3641. 3 indexed citations
20.
Kelleher, Dennis, Kelly Hardes, Noushin Brealey, et al.. (2013). Effect of severe renal impairment (SRI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK). 42. 4148. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jean Brooks Breakdown of academic impact, for papers by Sally Kilbride Breakdown of academic impact, for papers by Frank Barnhart Breakdown of academic impact, for papers by Lucy Frith Breakdown of academic impact, for papers by Marcia L. Erbland Breakdown of academic impact, for papers by Earl St. Rose Breakdown of academic impact, for papers by Pilar Román Sánchez Breakdown of academic impact, for papers by A. Dixmier Breakdown of academic impact, for papers by Nassrin Payvandi Breakdown of academic impact, for papers by Shireen Mirza
Rankless by CCL
2026